Christine Lindsay Mummery

Christine Lindsay Mummery

Top Cited Scholar 2026
Auto-generated profile, based on publicly available information

Christine Lindsay Mummery

Department of Anatomy and Embryology, Leiden University Medical Center, Leiden, The Netherlands

Research Focus & Metrics

Academic Career Length

46Years (1981-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 June 2003 in Circulation
Verified
Journal Article
Closed access
PDF file
CMChristine Mummery
Christine Mummery
DODorien Ward-Van Oostwaard
Dorien Ward-Van Oostwaard
PDPieter Doevendans
Pieter Doevendans
RSRene Spijker
Rene Spijker
SBStieneke van Den Brink
Stieneke van Den Brink
LTLeon Tertoolen
Leon Tertoolen
Background— Cardiomyocytes derived from human embryonic stem (hES) cells could be useful in restoring heart function after myocardial infarction or in heart failure. Here, we induced cardiomyocyte differentiation of hES cells by a novel method and compared their electrophysiological properties and coupling with those of primary human fetal cardiomyocytes. Methods and Results— hES cells were cocultured with visceral-endoderm (VE)–like cells from the mouse. This initiated differentiation to beating muscle. Sarcomeric marker proteins, chronotropic responses, and ion channel expression and function were typical of cardiomyocytes. Electrophysiology demonstrated that most cells resembled human fetal ventricular cells. Real-time intracellular calcium measurements, Lucifer yellow injection, and connexin 43 expression demonstrated that fetal and hES-derived cardiomyocytes are coupled by gap junctions in culture. Inhibition of electrical responses by verapamil demonstrated the presence of functional α 1c -calcium ion channels. Conclusions— This is the first demonstration of induction of cardiomyocyte differentiation in hES cells that do not undergo spontaneous cardiogenesis. It provides a model for the study of human cardiomyocytes in culture and could be a step forward in the development of cardiomyocyte transplantation therapies.

17 July 2007 in Circulation
Verified
Journal Article
Closed access
Thomas ThumThomas Thum
Thomas Thum
PGPaolo Galuppo
Paolo Galuppo
CWChristian Wolf
Christian Wolf
JFJan Fiedler
Jan Fiedler
SKSusanne Kneitz
Susanne Kneitz
JBJohann Bauersachs
Johann Bauersachs
Background— Chronic heart failure is characterized by left ventricular remodeling and reactivation of a fetal gene program; the underlying mechanisms are only partly understood. Here we provide evidence that cardiac microRNAs, recently discovered key regulators of gene expression, contribute to the transcriptional changes observed in heart failure. Methods and Results— Cardiac transcriptome analyses revealed striking similarities between fetal and failing human heart tissue. Using microRNA arrays, we discovered profound alterations of microRNA expression in failing hearts. These changes closely mimicked the microRNA expression pattern observed in fetal cardiac tissue. Bioinformatic analysis demonstrated a striking concordance between regulated messenger RNA expression in heart failure and the presence of microRNA binding sites in the respective 3′ untranslated regions. Messenger RNAs upregulated in the failing heart contained preferentially binding sites for downregulated microRNAs and vice versa. Mechanistically, transfection of cardiomyocytes with a set of fetal microRNAs induced cellular hypertrophy as well as changes in gene expression comparable to the failing heart. Conclusions— Our data support a novel mode of regulation for the transcriptional changes in cardiac failure. Reactivation of a fetal microRNA program substantially contributes to alterations of gene expression in the failing human heart.

20 July 2012 in Circulation Research
Verified
Journal Article
Closed access
PDF file
CMChristine L. Mummery
Christine L. Mummery
JZJianhua Zhang
Jianhua Zhang
ENElizabeth S. Ng
Elizabeth S. Ng
DEDavid A. Elliott
David A. Elliott
AEAndrew G. Elefanty
Andrew G. Elefanty
TKTimothy Kamp
Timothy Kamp
Since human embryonic stem cells were first differentiated to beating cardiomyocytes a decade ago, interest in their potential applications has increased exponentially. This has been further enhanced over recent years by the discovery of methods to induce pluripotency in somatic cells, including those derived from patients with hereditary cardiac diseases. Human pluripotent stem cells have been among the most challenging cell types to grow stably in culture, but advances in reagent development now mean that most laboratories can expand both embryonic and induced pluripotent stem cells robustly using commercially available products. However, differentiation protocols have lagged behind and in many cases only produce the cell types required with low efficiency. Cardiomyocyte differentiation techniques were also initially inefficient and not readily transferable across cell lines, but there are now a number of more robust protocols available. Here, we review the basic biology underlying the differentiation of pluripotent cells to cardiac lineages and describe current state-of-the-art protocols, as well as ongoing refinements. This should provide a useful entry for laboratories new to this area to start their research. Ultimately, efficient and reliable differentiation methodologies are essential to generate desired cardiac lineages to realize the full promise of human pluripotent stem cells for biomedical research, drug development, and clinical applications.

1 October 2003 in Molecular Cell
Verified
Journal Article
Closed access
MGMarie-José Goumans
Marie-José Goumans
GVGudrun Valdimarsdottir
Gudrun Valdimarsdottir
SISusumu Itoh
Susumu Itoh
FLFrank Lebrin
Frank Lebrin
JLJonas Larsson
Jonas Larsson
PDPeter Ten Dijke
Peter Ten Dijke

1 June 2020 in Cell Stem Cell
Verified
Journal Article
Open access
EGElisa Giacomelli
Elisa Giacomelli
Viviana MeravigliaViviana Meraviglia
Viviana Meraviglia
GCGiulia Campostrini
Giulia Campostrini
ACAmy Cochrane
Amy Cochrane
XCXu Cao
Xu Cao
CMChristine L. Mummery
Christine L. Mummery
Cardiomyocytes (CMs) from human induced pluripotent stem cells (hiPSCs) are functionally immature, but this is improved by incorporation into engineered tissues or forced contraction. Here, we showed that tri-cellular combinations of hiPSC-derived CMs, cardiac fibroblasts (CFs), and cardiac endothelial cells also enhance maturation in easily constructed, scaffold-free, three-dimensional microtissues (MTs). hiPSC-CMs in MTs with CFs showed improved sarcomeric structures with T-tubules, enhanced contractility, and mitochondrial respiration and were electrophysiologically more mature than MTs without CFs. Interactions mediating maturation included coupling between hiPSC-CMs and CFs through connexin 43 (CX43) gap junctions and increased intracellular cyclic AMP (cAMP). Scaled production of thousands of hiPSC-MTs was highly reproducible across lines and differentiated cell batches. MTs containing healthy-control hiPSC-CMs but hiPSC-CFs from patients with arrhythmogenic cardiomyopathy strikingly recapitulated features of the disease. Our MT model is thus a simple and versatile platform for modeling multicellular cardiac diseases that will facilitate industry and academic engagement in high-throughput molecular screening.

23 September 2004 in The EMBO Journal
Verified
Journal Article
Open access
PDF file
FLFrank Lebrin
Frank Lebrin
MGMarie-José Goumans
Marie-José Goumans
LJLeon Jonker
Leon Jonker
RCRita Lc Carvalho
Rita Lc Carvalho
GVGudrun Valdimarsdottir
Gudrun Valdimarsdottir
PDPeter Ten Dijke
Peter Ten Dijke
Endoglin is a transmembrane accessory receptor for transforming growth factor‐β (TGF‐β) that is predominantly expressed on proliferating endothelial cells in culture and on angiogenic blood vessels in vivo . Endoglin, as well as other TGF‐β signalling components, is essential during angiogenesis. Mutations in endoglin and activin receptor‐like kinase 1 (ALK1), an endothelial specific TGF‐β type I receptor, have been linked to the vascular disorder, hereditary haemorrhagic telangiectasia. However, the function of endoglin in TGF‐β/ALK signalling has remained unclear. Here we report that endoglin is required for efficient TGF‐β/ALK1 signalling, which indirectly inhibits TGF‐β/ALK5 signalling. Endothelial cells lacking endoglin do not grow because TGF‐β/ALK1 signalling is reduced and TGF‐β/ALK5 signalling is increased. Surviving cells adapt to this imbalance by downregulating ALK5 expression in order to proliferate. The ability of endoglin to promote ALK1 signalling also explains why ectopic endoglin expression in endothelial cells promotes proliferation and blocks TGF‐β‐induced growth arrest by indirectly reducing TGF‐β/ALK5 signalling. Our results indicate a pivotal role for endoglin in the balance of ALK1 and ALK5 signalling to regulate endothelial cell proliferation.